View Archive

Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Natera, Inc.

Oncology Best Practice™ Series: Key Questions for the Community on the Detection and Treatment of MRD

Oncology Best Practice™ Series: Key Questions for the Community on the Detection and Treatment of MRD

October 28, 2021


Minimal residual disease (MRD) has emerged as a valuable tool in hematologic malignancies, helping clinicians to both predict prognosis and individualize therapy. In patients with solid tumors, MRD testing using cell-free nucleic acids released from malignant cells are being studied for similar roles in predicting patient outcomes and helping to select therapy. Technological advances have resulted in the use of circulating tumor DNA (ctDNA) as a way to examine the tumor genome, monitor treatment response, detect early relapse, assess the development of drug resistance, and evaluate MRD. 
In this dinner meeting program, experts will review the emergence of MRD as a tool in the management of patients with solid tumors. The results  of MRD research across tumor types, and the latest testing methods and technologies used to assess MRD will be reviewed. The clinical impact of using MRD to assess early relapse will be examined. In addition, the audience is invited to bring patient cases to review the role, or potential role, of MRD in the care of patients with a variety of solid tumors, including lung, colorectal, and skin cancers.

Benefits of Attending

  • Review tests and technologies available for MRD testing
  • Analyze the role of MRD in monitoring treatment response and detecting early relapse
  • Discuss cases from the audience regarding the potential role of MRD in the management of patients with solid tumors

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Natera, Inc.

Target Audience

This educational activity is directed toward academic and community-based oncologists, pathologists, hematologists, nurse practitioners (NPs), pharmacists, physician assistants (PAs) and other health care professionals involved in the detection and treatment of MRD.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Assess evolving methods to predict relapse among patients with solid tumors
  • Explain the rationale underlying the application of ctDNA testing technologies to identify MRD among patients with solid tumors 
  • Describe clinical trial findings in which MRD has been used to monitor patients for early relapse or response in solid tumor settings, including gastrointestinal malignancies
  • Determine how recent evidence in the use of MRD can be considered in real-world clinical scenarios in which patients with solid tumors are monitored for risk of recurrence or early relapse


2 Ways to Register
  1. Online: click here.
  2. Phone: Please call (888) 949-0045 or (609) 378-3701

Physicians' Education Resource®
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
Registration Fee - Free

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®, LLC (PER®) fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

By attending a PER® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image"). By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.

Meeting information is accurate at the time of posting.

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

In case of onsite emergency:

Professional Information


Assumption of Risk and Waiver of Liability Relating to Coronavirus/COVID-19

I understand that the hazards of the novel coronavirus ("COVID-19") and have reviewed the Centers for Disease Control and Prevention ("CDC") current guidelines in regards to COVID-19. I acknowledge that while Physicians' Education Resource, LLC ("PER") ("Company") has put in place preventive measures to reduce the spread of COVID-19, Company cannot guarantee that I or anyone else will not become infected with COVID-19. I attest that if within the fourteen (14) days prior to the event, I am experiencing any symptoms of COVID-19, I will not attend the Activities. I shall follow any safety, social distancing, masking, and hygiene protocols that have been implemented at the Activities, including providing proof at check in of being 2 weeks removed from receiving a full COVID-19 vaccination or results from a negative COVID-19 viral test taken no more than 3 days prior to the program.

I hereby willingly and voluntarily choose to attend this PER event and related activities ("Activity"). I acknowledge and fully assume the risk and hazards of exposure to COVID-19 and that such exposure or infection may result in personal injury, illness, permanent disability, and death to myself, my spouse, children, unborn child, or relatives. I acknowledge that Company may share my personal information for the purpose of contact tracing if the need arises, and I hereby consent to the release of my personal information for such purpose. I hereby release covenant not to sue, forever discharge, and hold harmless Company and its affiliates from all liability claims and demands of whatever kind of nature, either in law or in equity, which arise or may hereafter arise from participating in the Activities. I assume all risks of losses, damages, or injuries that may be sustained while participating in the Activity. I understand and agree that this release includes any Claims based on the actions, omissions, or negligence of the venue, employees, vendors, agents, and representatives, whether a COVID-19 infection occurs before, during, or after participation in the Activity.

* By checking this box, you have read and understand the above and agree to its terms.

Calendar of Events
Filter By